CA3044262A1 - Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci - Google Patents

Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci

Info

Publication number
CA3044262A1
CA3044262A1 CA3044262A CA3044262A CA3044262A1 CA 3044262 A1 CA3044262 A1 CA 3044262A1 CA 3044262 A CA3044262 A CA 3044262A CA 3044262 A CA3044262 A CA 3044262A CA 3044262 A1 CA3044262 A1 CA 3044262A1
Authority
CA
Canada
Prior art keywords
transcript
cancer
mtdna
mitochondrial
transcripts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3044262A
Other languages
English (en)
Other versions
CA3044262C (fr
Inventor
Ryan Parr
Brian Reguly
Gabriel Dakubo
Jennifer Creed
Kerry Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDNA LIFE SCIENCES Inc
Original Assignee
MDNA LIFE SCIENCES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDNA LIFE SCIENCES Inc filed Critical MDNA LIFE SCIENCES Inc
Publication of CA3044262A1 publication Critical patent/CA3044262A1/fr
Application granted granted Critical
Publication of CA3044262C publication Critical patent/CA3044262C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • C12Q1/6874Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Il est décrit de nouvelles transcriptions de fusion mitochondriale ainsi que les molécules dADNmt mutée parente utiles pour la prévision, le diagnostic et/ou la surveillance du cancer. Il est également décrit des sondes dhybridation complémentaires prévues pour lutilisation dans le cadre de méthodes décrites.
CA3044262A 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci Active CA3044262C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4061608P 2008-03-28 2008-03-28
US61/040,616 2008-03-28
CA2719718A CA2719718C (fr) 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2719718A Division CA2719718C (fr) 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci

Publications (2)

Publication Number Publication Date
CA3044262A1 true CA3044262A1 (fr) 2009-10-01
CA3044262C CA3044262C (fr) 2023-02-28

Family

ID=41112880

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3044262A Active CA3044262C (fr) 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci
CA2719718A Expired - Fee Related CA2719718C (fr) 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2719718A Expired - Fee Related CA2719718C (fr) 2008-03-28 2009-03-27 Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci

Country Status (10)

Country Link
US (4) US20110172113A1 (fr)
EP (1) EP2274426B1 (fr)
JP (1) JP5938690B2 (fr)
KR (2) KR101819852B1 (fr)
CN (3) CN107011428B (fr)
AU (1) AU2009227935B2 (fr)
CA (2) CA3044262C (fr)
NZ (2) NZ602175A (fr)
SG (3) SG192453A1 (fr)
WO (1) WO2009117811A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602175A (en) 2008-03-28 2014-03-28 Mitomics Inc Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
EP3272871B1 (fr) * 2009-03-27 2020-01-15 MDNA Life Sciences Inc. Adn mitochondrial aberrant, transcription de fusion associées, produits de translation et sondes d'hybridation associées
WO2011106892A1 (fr) * 2010-03-01 2011-09-09 Mitomics Inc. Produits de transcription de fusion d'adn-mt associés aux uv et méthodes et utilisations de ceux-ci
WO2012021512A2 (fr) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Agents thérapeutiques se liant aux érythrocytes
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA3029211A1 (fr) * 2016-06-22 2017-12-28 Degen Zhuo Procede et kit de detection de produits de transcription de fusion
US11978535B2 (en) * 2017-02-01 2024-05-07 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
EP3774890A4 (fr) * 2018-03-26 2022-05-04 The University of Chicago Procédés et compositions permettant de cibler une lectine de type c de cellules endothéliales sinusoïdales du foie et des ganglions lymphatiques (lsectine)
CN117384269B (zh) * 2023-09-21 2024-06-18 南方医科大学南方医院 短肽mfrlp及其在制备动脉重塑相关疾病药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6605433B1 (en) * 1998-08-20 2003-08-12 The Johns Hopkins University Mitochondrial dosimeter
US6203990B1 (en) * 1998-11-06 2001-03-20 Mitokor Method and system for pattern analysis, such as for analyzing oligonucleotide primer extension assay products
US6933120B2 (en) * 2000-06-20 2005-08-23 Michael D. Seidman Method of determining biological/molecular age
JP2005506057A (ja) * 2001-06-11 2005-03-03 1304854 オンタリオ・リミテッド 健康科学のための診断ツールとしての全ミトコンドリアゲノム配列
US20030162174A1 (en) * 2001-06-11 2003-08-28 Sutherland John W. Detecting nucleic acid deletion sequences
US20050026167A1 (en) * 2001-06-11 2005-02-03 Mark Birch-Machin Complete mitochondrial genome sequences as a diagnostic tool for the health sciences
GB2380194B (en) * 2001-10-01 2005-06-22 Roger Michael Marchbanks A mitochondrial mutation associated with schizophrenia and increased oxidative stress
US20060051796A1 (en) * 2004-09-09 2006-03-09 Inga Boell Real time PCR with the addition of pyrophosphatase
EP2339032B1 (fr) * 2005-04-18 2016-12-28 MDNA Life Sciences Inc. Mutations mitochondriales et réagencements en tant qu'outil de diagnostic pour la détection de l'exposition au soleil, cancer de la prostate et autres cancers
US20070134678A1 (en) * 2005-12-12 2007-06-14 Rees Dianne M Comparative genome hybridization of organelle genomes
ES2484044T3 (es) 2007-09-26 2014-08-08 Mitomics Inc. Deleción de 3,4 kb en el ADN mitocondrial para uso en la detección de cáncer
NZ602175A (en) * 2008-03-28 2014-03-28 Mitomics Inc Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
EP3272871B1 (fr) 2009-03-27 2020-01-15 MDNA Life Sciences Inc. Adn mitochondrial aberrant, transcription de fusion associées, produits de translation et sondes d'hybridation associées
WO2011106892A1 (fr) * 2010-03-01 2011-09-09 Mitomics Inc. Produits de transcription de fusion d'adn-mt associés aux uv et méthodes et utilisations de ceux-ci

Also Published As

Publication number Publication date
KR20110004860A (ko) 2011-01-14
US20170152567A1 (en) 2017-06-01
CN102388140A (zh) 2012-03-21
SG10201400985RA (en) 2014-05-29
KR101819852B1 (ko) 2018-02-28
WO2009117811A1 (fr) 2009-10-01
EP2274426A1 (fr) 2011-01-19
NZ602175A (en) 2014-03-28
CN102388140B (zh) 2015-07-08
AU2009227935B2 (en) 2015-07-09
CN107011428A (zh) 2017-08-04
NZ588658A (en) 2012-10-26
US20130059299A1 (en) 2013-03-07
US20190382846A1 (en) 2019-12-19
EP2274426A4 (fr) 2011-11-16
SG174514A1 (en) 2011-10-28
US20110172113A1 (en) 2011-07-14
CA3044262C (fr) 2023-02-28
CN102016039A (zh) 2011-04-13
KR101693387B1 (ko) 2017-01-05
CN107011428B (zh) 2022-02-25
JP5938690B2 (ja) 2016-06-22
US10266899B2 (en) 2019-04-23
CA2719718C (fr) 2019-07-02
CA2719718A1 (fr) 2009-10-01
AU2009227935A1 (en) 2009-10-01
SG192453A1 (en) 2013-08-30
JP2011515091A (ja) 2011-05-19
US8715960B2 (en) 2014-05-06
KR20170004033A (ko) 2017-01-10
CN102016039B (zh) 2017-06-09
EP2274426B1 (fr) 2016-11-16

Similar Documents

Publication Publication Date Title
CA3044262C (fr) Adn mitochondrial aberrant, produits de transcription de fusion associes et sondes d'hybridation pour celui-ci
KR101074841B1 (ko) 방광암 특이적 메틸화 마커 유전자를 이용한 방광암 진단용키트 및 칩
US20130065789A1 (en) Compositions and methods for classifying lung cancer and prognosing lung cancer survival
KR101825117B1 (ko) Pna 기반의 실시간 pcr 클램핑을 이용한 braf 돌연변이 검출 방법 및 키트
AU2010234238B2 (en) Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor
KR101255768B1 (ko) 자궁경부암 특이적 메틸화 유전자의 CpG 섬을 함유하는 자궁경부암 또는 자궁경부암 진행단계 진단용 바이오마커
KR101064561B1 (ko) 폐선암 수술 후 초기 재발 예측용 바이오마커
EP1038026B1 (fr) Analyse diagnostique permettant de determiner la susceptibilite au cancer
KR101323101B1 (ko) 유방암 또는 난소암의 유전성 소인 예측에 유용한 brca2 유전자 돌연변이
CA2756824A1 (fr) Adn mitochondrial aberrant, transcrits de fusion et produits de traduction associes et sondes d'hybridation complementaires
WO2016083466A1 (fr) Nouveau gène suppresseur de tumeur et utilisations de celui-ci pour le traitement et le diagnostic du cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527

EEER Examination request

Effective date: 20190527